Gyre Therapeutics (GYRE) Revenue Growth (3y) (2013 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 122.97% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 7.94% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 4.47% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 54.05% |
| 10 | Gyre Therapeutics | 532.38 Mn | 518.25 Mn | 8.38 Mn | -3.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.33% |
| Dec 31, 2025 | -28.44% |
| Mar 31, 2025 | 202.86% |
| Dec 31, 2024 | 125.21% |
| Sep 30, 2024 | 122.98% |
| Jun 30, 2024 | 181.40% |
| Mar 31, 2024 | 164.58% |
| Dec 31, 2023 | 137.32% |
| Sep 30, 2023 | 229.83% |
| Jun 30, 2023 | 160.56% |
| Mar 31, 2023 | 15.06% |
| Mar 31, 2021 | 525.31% |
| Dec 31, 2020 | 85.54% |
| Sep 30, 2020 | 41.08% |
| Jun 30, 2020 | 146.28% |
| Mar 31, 2020 | 292.34% |
| Mar 31, 2018 | -79.25% |
| Dec 31, 2017 | -22.07% |
| Sep 30, 2017 | -16.54% |
| Jun 30, 2017 | -27.97% |
| Mar 31, 2017 | -3.01% |
| Dec 31, 2016 | -8.60% |
| Mar 31, 2016 | -68.65% |
| Dec 31, 2015 | -43.05% |
| Sep 30, 2015 | -47.84% |
| Jun 30, 2015 | -70.55% |
| Mar 31, 2015 | -69.14% |
| Dec 31, 2014 | -67.14% |
| Sep 30, 2014 | -69.33% |
| Jun 30, 2014 | -75.72% |
| Mar 31, 2014 | -80.32% |
| Dec 31, 2013 | -83.81% |